Tunlametinib is a pharmaceutical drug for the treatment of cancer.

It is an inhbitor of mitogen-activated protein kinase kinase.

[1] In China, tunlametinib was approved in 2024 for the treatment of patients with NRAS-mutated advanced melanoma who were previously treated with a PD-1/PD-L1 targeting agent.

[2][3] It is also being studied for use in combination with vemurafenib in patients with advanced BRAF V600-mutant solid tumors.

This antineoplastic or immunomodulatory drug article is a stub.